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A B S T R A C T
The anticancer drug ellipticine exerts its genotoxic eﬀects after metabolic activation by cytochrome P450 (CYP)
enzymes. The present study has examined the role of cytochrome P450 oxidoreductase (POR) and cytochrome b5
(Cyb5), electron donors to P450 enzymes, in the CYP-mediated metabolism and disposition of ellipticine in vivo.
We used Hepatic Reductase Null (HRN) and Hepatic Cytochrome b5/P450 Reductase Null (HBRN) mice. HRN
mice have POR deleted speciﬁcally in hepatocytes; HBRN mice also have Cyb5 deleted in the liver. Mice were
treated once with 10mg/kg body weight ellipticine (n=4/group) for 24 h. Ellipticine-DNA adduct levels
measured by 32P-postlabelling were signiﬁcantly lower in HRN and HBRN livers than in wild-type (WT) livers;
however no signiﬁcant diﬀerence was observed between HRN and HBRN livers. Ellipticine-DNA adduct for-
mation in WT, HRN and HBRN livers correlated with Cyp1a and Cyp3a enzyme activities measured in hepatic
microsomes in the presence of NADPH conﬁrming the importance of P450 enzymes in the bioactivation of
ellipticine in vivo. Hepatic microsomal fractions were also utilised in incubations with ellipticine and DNA in the
presence of NADPH, cofactor for POR, and NADH, cofactor for Cyb5 reductase (Cyb5R), to examine ellipticine-
DNA adduct formation. With NADPH adduct formation decreased as electron donors were lost which correlated
with the formation of the reactive metabolites 12- and 13-hydroxy-ellipticine in hepatic microsomes. No dif-
ference in adduct formation was observed in the presence of NADH. Our study demonstrates that Cyb5 con-
tributes to the P450-mediated bioactivation of ellipticine in vitro, but not in vivo.
1. Introduction
Ellipticine (5,11-dimethyl-6H-pyrido[4,5-b]carbazole) is a cytotoxic
alkaloid isolated from the Apocynaceae family of plants. Both ellipticine
and its derivatives possess anti-HIV and anti-tumour properties al-
lowing it to be used against several cancers with limited toxic side ef-
fects and no haematological toxicity by functioning through multiple
mechanisms that result in cell cycle arrest and initiation of apoptosis
(Martinkova et al., 2010; Stiborova et al., 2011; Miller and McCarthy,
2012; Stiborova and Frei, 2014). The main mechanisms by which el-
lipticine exerts its anti-tumour, cytotoxic and mutagenic eﬀects are
inhibition of topoisomerase II, intercalation into DNA and enzyme-
mediated formation of covalent ellipticine-derived DNA adducts
(Garbett and Graves, 2004; Stiborova and Frei, 2014; Banerjee et al.,
2015; Vann et al., 2016).
Ellipticine needs to be metabolised to exert its pharmacological ef-
fects. These enzyme-catalysed reactions also generate detoxication
products leading to the excretion of the drug. Activation of ellipticine
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(i.e. generation of pharmacologically active metabolites) is catalysed by
cytochrome P450 (CYP) enzymes and peroxidases, which generate re-
active intermediates capable of damaging DNA by forming covalent
adducts (Stiborova et al., 2001; Stiborova et al., 2003; Stiborova et al.,
2003; Stiborova et al., 2007; Stiborova et al., 2007; Stiborova et al.,
2008; Stiborova et al., 2012; Stiborova et al., 2012). As shown in Fig. 1,
ellipticine is oxidised by P450 enzymes to form ﬁve metabolites, in-
cluding the reactive metabolites 12-hydroxy- and 13-hydroxy-ellipti-
cine which dissociate to ellipticine-12-ylium and ellipticine-13-ylium
and bind to DNA (Stiborova et al., 2004; Aimova et al., 2007; Stiborova
et al., 2014; Stiborova and Frei, 2014; Stiborova et al., 2014). The N2-
oxide is also considered an active ellipticine metabolite as it converts to
Fig. 1. Pathways of biotransformation and DNA adduct formation of ellipticine catalysed by P450 and peroxidase enzymes showing the identiﬁed metabolites and
those proposed to form DNA adducts. The compounds shown in brackets have not been previously detected under experimental conditions and/or not structurally
characterised.
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12-hydroxy-ellipticine by the Polonowski rearrangement (Stiborova
et al., 2004; Kotrbova et al., 2006). 7-Hydroxy-ellipticine and 9-hy-
droxy-ellipticine are considered detoxication metabolites due to their
eﬃcient excretion by experimental animals (Stiborova et al., 2012;
Stiborova et al., 2012). Therefore, understanding the role of P450 en-
zymes in ellipticine metabolism is important both pharmacologically
and toxicologically.
A number of transgenic mouse lines (e.g. CYP-knockout or CYP-
humanised) have been applied to study the contribution of individual
P450 enzymes to chemical-induced genotoxicity and carcinogenesis
(Stiborova et al., 2012; Nebert et al., 2013; Reed et al., 2018). However,
due to the large number of CYP enzymes it has been diﬃcult to de-
termine the in vivo role of P450 enzymes as a whole as there are
overlapping substrate speciﬁcities. We have used the Hepatic P450
Reductase Null (HRN) mouse model in order to overcome this limita-
tion (Arlt et al., 2015). HRN mice have a deletion of NADPH:cyto-
chrome P450 oxidoreductase (POR), the predominant electron donor to
P450s, speciﬁcally in their hepatocytes (Henderson et al., 2003). This
deletion results in the loss of essentially all hepatic P450 activity and
the mice have been used to investigate hepatic versus extra-hepatic
P450 mediated metabolism of several carcinogens including ellipticine
(Arlt et al., 2005; Stiborova et al., 2008; Levova et al., 2011; Arlt et al.,
2012). HRN mice formed 65% lower levels of ellipticine-DNA adducts
in their livers than wild-type (WT) mice, demonstrating the importance
of P450 activity in the hepatic bioactivation of ellipticine (Stiborova
et al., 2008).
Although POR is viewed as the predominant electron donor to P450
enzymes, cytochrome b5 (Cyb5) can also act as the electron donor
(Yamazaki et al., 2002; Finn et al., 2008). Cyb5 can modulate P450
activity in three ways: (i) by direct transfer of both electrons via cyto-
chrome b5 reductase (Cyb5R) in a pathway independent of POR
(Yamazaki et al., 1996; Yamazaki et al., 1996); (ii) by transfer of the
second electron from either POR or Cyb5R (Zhang et al., 2007); or (iii)
by acting as an allosteric modiﬁer of the enzyme in a non-catalytic role
that can enhance reactions for many, but not all, P450 enzymes
(Yamazaki et al., 2002). Cyb5 is both substrate and enzyme speciﬁc,
and has been shown to both stimulate and inhibit P450 reactions,
making it diﬃcult to predict the contribution of Cyb5 to xenobiotic
metabolism.
Previous studies using reconstituted systems investigated the role of
Cyb5 in the metabolic activation of ellipticine in vitro showed that the
presence of Cyb5 resulted in a considerable increase in the activation
metabolites 12-hydroxy- and 13-hydroxyellipticine (Kotrbova et al.,
2011; Stiborova et al., 2012; Stiborova et al., 2012; Stiborova et al.,
2017). The formation of ellipticine-DNA adducts was also shown to
increase ~6-fold in the case of CYP1A1, ~4-fold for CYP1A2 and ~3-
fold for CYP3A4 (Kotrbova et al., 2011; Stiborova et al., 2012). These
ﬁndings were supported by studies using human recombinant P450s in
Supersomes™ with CYP3A4 and 1A1 being the most eﬃcient at forming
ellipticine-DNA adduct 1 and with adduct 2 being formed by CYP2C19,
2C9 and 2D6 in the presence of Cyb5 (Stiborova et al., 2012). Rats
exposed to ellipticine have also shown a signiﬁcant increase in the
expression of both Cyb5 mRNA and protein, and hepatic microsomes
isolated from these rats catalysed ellipticine oxidation more eﬃciently
(Stiborova et al., 2016). Together these studies provide evidence for the
role of Cyb5 in the bioactivation of ellipticine both in vitro and in vivo.
Hepatic Cytochrome b5/P450 Reductase Null (HBRN) mice
(Henderson et al., 2014) lack both POR and Cyb5 in their livers and
have reduced P450 activity relative to HRN mice (Henderson et al.,
2013). In the present study we have used both the HRN and HBRN
mouse lines to investigate the contribution of Cyb5 to the metabolic
activation of ellipticine to form DNA adducts in vivo alongside micro-
somal incubations to investigate metabolite and DNA adduct formation
in vitro. Hepatic microsomal P450 enzyme activity and protein ex-
pression have also been assessed.
2. Materials and methods
2.1. Chemicals
Ellipticine, NADH (as disodium salt; purity ~95%), NADPH (as
tetrasodium salt; ~98% purity), Sudan I and 7-methoxyresoruﬁn were
obtained from Sigma Chemical Co (St Louis, MO, USA). Testosterone
and 6β-hydroxytestosterone were purchased from Merck (Darmstadt,
Germany).
2.2. Animal treatment
All animal experiments were carried out at the University of Dundee
under licence in accordance with the Animal (Scientiﬁc Procedures) Act
(1986), as amended by EU Directive 2010/63/EU, and with local
ethical approval. HRN (Porlox/lox/CreCYP1A1) mice and HBRN (Cytb5lox/
lox/Porlox/lox ± CreALB) mice on a C57BL/6 background were derived as
described previously (Henderson et al., 2003; Henderson et al., 2013).
Animals were maintained in open-top cages, with free access to food
(RM1 diet, Special Diet Services, Essex, UK) and water, and a 12-h
light/dark cycle. Mice homozygous for the ﬂoxed Por locus (Porlox/lox)
were used as wild-type (WT). Groups of female HRN, HBRN and WT
mice (3months old, 25–30 g) were treated intraperitoneally (i.p.) with
10mg/kg body wt ellipticine (n=4/group) based on a treatment re-
gimen used previously in HRN mice (Stiborova et al., 2008). Ellipticine
was administered dissolved in 1% acetic acid at a concentration of
2.5 mg/ml. Control mice (n=3/group) received the solvent only. An-
imals were killed 24 h after the single dose and their tissues (liver, lung,
small intestine, kidney, spleen, bladder and colon) were collected, snap-
frozen and stored at −80 °C until analysis.
2.3. Ellipticine-DNA adduct detection by 32P-postlabelling analysis
Genomic DNA from whole tissue was isolated by a standard phenol-
chloroform extraction method and DNA adducts were measured for
each DNA sample using the nuclease P1 enrichment version of the thin-
layer chromatography (TLC)-32P-postlabelling method as described
previously (Stiborova et al., 2008; Willis et al., 2018). Solvents used
were: D1, 1.0M sodium phosphate, pH 6.0; D3, 3.5 M lithium formate,
8.5 M urea, pH 4.0; D4, 0.8 M LiCl, 0.5M Tris, 8.5 M urea, pH 9.0. After
chromatography TLC plates were scanned using a Packard Instant Im-
ager (Dowers Grove, IL, USA). DNA adduct levels were calculated from
the adduct cpm, the speciﬁc activity of [γ-32P]ATP and the amount of
DNA (pmol of DNA-P) used and results were expressed as DNA adducts/
108 nucleotides.
2.4. Preparation of microsomes
Hepatic microsomes from ellipticine-treated mice were isolated as
described previously (Reed et al., 2018). Microsomes were isolated
from 4 pooled livers of each mouse model. Protein concentration in the
microsomal fraction was measured using the bicinchoninic acid protein
assay with bovine serum albumin as standard. Pooled microsomal
fractions were used for further experiments.
2.5. Enzyme activity assays and immunoblotting
The hepatic microsomal fractions were characterised for Cyp1a1
enzyme activity using Sudan I oxidation (Stiborova et al., 2002), for
Cyp1a2 enzyme activity using 7-methoxyresoruﬁn O-demethylation
(MROD) (Burke et al., 1994), for Cyp1a1/2 enzyme activity using 7-
ethoxyresoruﬁn O-deethylation (EROD) (Stiborova et al., 2005) and for
Cyp3a enzyme activity using testosterone 6β-hydroxylation (Stiborova,
et al., 2017). POR enzyme activity was determined as described pre-
viously (Arlt et al., 2003). Western blotting analysis using 4–12% Bis-
Tris gradient gels and sodium dodecyl sulphate-polyacrylamide gel
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electrophoresis (SDS-PAGE) were carried out as described previously
(Reed et al., 2018). After migration the proteins were transferred onto
polyvinylidene diﬂuoride (PVDF) membranes and the following pri-
mary antibodies were used: anti-Cyp1a1 1:1000 (sc-20,772 (H-70),
Santa Cruz Biotech); anti-Cyp3a 1:20000 (ab3572, Abcam); anti-Por
1:1000 (ab39995, Abcam), anti-Cyb5 1:750 (ab69801, Abcam); and
anti-Cyb5R 1:1000 (ABIN453978, antibodies-online.com). The anti-
body to detect glyceraldehyde phosphate dehydrogenase (Gapdh)
1:25000 (MAB374, Chemicon) was used as loading control. The sec-
ondary horseradish peroxidase-linked antibodies were as follows: anti-
goat 1:10000 (sc-2020, Santa Cruz) anti-rabbit 1:10000 (#170–5046,
BioRad). The antigen-antibody complex was visualised using Super-
Signal® West Pico Chemiluminescent Substrate Kit (Thermo Scientiﬁc).
2.6. Microsomal incubations for ellipticine-DNA adduct formation
Incubation mixtures consisted of 100mM potassium phosphate
buﬀer (pH 7.4). Reduced nicotinamide adenine dinucleotide (NADPH)
or reduced form of nicotinamide adenine dinucleotide (NADH) (10mM
in each case), pooled hepatic microsomal fraction (0.5 mg/ml protein)
from ellipticine-pretreated HRN, HBRN and WT mice, 0.1mM ellipti-
cine dissolved in 7.5 μl methanol and calf thymus DNA (0.5mg) in a
ﬁnal volume of 750 μl. Incubations were carried out at 37 °C for 90min
(Aimova et al., 2008). Control incubations were carried out (i) without
microsomes; (ii) without NADPH or NADH; (iii) without DNA and (iv)
without ellipticine. After incubation, DNA was isolated by a standard
phenol-chloroform extraction method. Ellipticine-DNA adduct forma-
tion was determined by 32P-postlabelling as described above.
2.7. Microsomal incubations for studying ellipticine metabolism
Incubation mixtures contained 100mM potassium phosphate buﬀer
(pH 7.4), NADPH or NADH (1mM), 25 μM ellipticine dissolved in 5 μl
DMSO and pooled hepatic microsomal fraction (0.5 mg/ml protein) in a
ﬁnal volume of 500 μl. Incubations were carried out at 37 °C for 20min.
Control incubations were carried out (i) without microsomes; (ii)
without NADPH or NADH; (iii) without ellipticine. After incubation,
5 μl of 1 mM phenacetin (PA) in methanol was added as an internal
standard. Ellipticine metabolites were extracted twice with ethyl
acetate (1 ml), solvent evaporated to dryness, residues dissolved in 25 μl
methanol and ellipticine metabolites separated by high performance
liquid chromatography (HPLC) (5 μm Ultrasphere ODS Beckman,
4.6 mm×250mm preceded by a C18 guard column). The eluent was
64% methanol plus 36% of 5mM heptane sulfonic acid in 32mM acetic
acid in water with a ﬂow rate of 0.8 ml/min and detection was at
296 nm. Three ellipticine metabolites with the retention times of 5.7,
6.3 and 6.7min were separated (Stiborova et al., 2004; Kotrbova et al.,
2006; Stiborova et al., 2006).
2.8. Statistical analysis
Statistical analyses were performed with Prism GraphPad Software
(Version 7.04) and P < .05 was considered signiﬁcant.
3. Results
3.1. Protein expression of XMEs
Expression of electron donor proteins (i.e. POR, Cyb5, Cyb5R) as-
sociated with the mixed-function oxidase system (i.e. P450) were
probed for in the hepatic microsomal fractions from WT, HRN and
HBRN mice exposed to ellipticine (Fig. 2). POR was expressed in the WT
mice only and Cyb5 was expressed only in WT and HRN mice, as ex-
pected (Henderson et al., 2013; Reed et al., 2018). Cyb5R was ex-
pressed uniformly across all mouse lines. Cyp1a1 protein expression
was greater in HRN and HBRN hepatic microsomal fractions after
ellipticine treatment compared to WT. Cyp3a protein is constitutively
expressed across all mouse lines but expression was increased in HRN
and HBRN mice.
3.2. Enzyme activity of XMEs
POR activity was detected in the hepatic microsomal fractions from
WT mice but not in knockout animals (Fig. 3A) which is as expected
given the deletion of POR in the hepatocytes of HRN and HBRN mice
(Henderson et al., 2013; Arlt et al., 2015).
We used Sudan I oxidation (Fig. 3B), MROD (Fig. 3C) and EROD
(Fig. 3D) as measures of Cyp1a1, Cyp1a2 and Cyp1a enzyme activity,
respectively, and testosterone 6β-hydroxylation (Fig. 3E) as a measure
of Cyp3a enzyme activity. When the cofactor for POR, NADPH, was
used in the reaction mixture, hepatic microsomes from WT mice ex-
hibited the highest levels of Cyp1a activity, except for in EROD where
the levels of activity were equal in WT and HRN hepatic microsomal
fractions (compare Fig. 3C-E). According to the Sudan I oxidation and
MROD assays Cyp1a1/2 activity was signiﬁcantly lower in the hepatic
microsomes from HRN mice which correlated with the lack of POR
activity in HRN mice relative to WT mice. Cyp1a1/2 activity in hepatic
microsomes from HBRN mice was signiﬁcantly lower compared to WT
and HRN mice and showed the lowest level of Cyp1a1/2 activity when
NADPH was present. When NADPH was used in the reaction mixture,
hepatic microsomes from WT mice exhibited the highest level of Cyp3a
activity, with levels being greatly lower than in the HRN and HBRN
fractions.
When the cofactor for Cyb5R, NADH, was used in the reaction
mixture, hepatic microsomes from HRN mice showed signiﬁcantly
higher Cyp1a activity than the hepatic microsomal fractions from WT
and HBRN mice (Fig. 3B-D). Using MROD as a measure for Cyp1a2
activity, enzyme activity was similar in WT and HBRN mice (Fig. 3C).
Fig. 2. Western blot analysis of Cyp1a1, Cyp3a, POR, cytochrome b5 (Cyb5)
and cytochrome b5 (Cyb5R) reductase in the pooled hepatic microsomal frac-
tions of ellipticine-treated WT, HRN and HBRN mice (n=4/group). Gapdh
protein expression was used as a loading control. Representative images of the
Western blotting are shown, and at least duplicate analysis was performed in
separate experiments.
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When EROD and Sudan I oxidation were used as a measure for Cyp1a
activity hepatic microsomes from HBRN mice exhibited the lowest level
of Cyp1a activity in the presence of NADH (Fig. 3B and D). When NADH
was used in the reaction mixture, hepatic microsomes from HRN mice
showed signiﬁcantly higher Cyp3a activity than the hepatic microsomal
fractions from HBRN mice but not WT mice (Fig. 3E).
3.3. HPLC analysis of ellipticine metabolites
Hepatic microsomes isolated from WT, HRN and HBRN mice were
incubated with ellipticine and subsequently analysed by HPLC to de-
termine the ellipticine metabolite proﬁle. Representative HPLC chro-
matograms are shown in Fig. 4. Three metabolites were formed in the
microsomal incubations; 9-hydroxyellipticine (assigned peak M1), 12-
hydroxyellipticine (assigned peak M2) and 13-hydroxyellipticine (as-
signed peak M3) (Fig. 4A and B). No metabolites were detected in
control incubations without microsomes, without NADPH/NADH-gen-
erating system or without ellipticine (Fig. 4C and D). The total forma-
tion of metabolites was highest in the hepatic microsomal fraction from
WT mice when NADPH was used in the reaction mix (Fig. 5A). Total
ellipticine metabolite formation in hepatic microsomal fractions from
WT mice was around 3-fold higher compared to when NADH was used
(Fig. 5B). Hydroxylated ellipticine metabolites were identiﬁed and the
structures are shown in Fig. 1.
When using NADPH as cofactor the overall formation of metabolites
was signiﬁcantly lower in hepatic microsomal fractions from HRN mice
with production of 9-hydroxyellipticine and 13-hydroxyellipticine
being signiﬁcantly lower compared to WT, and 12-hydroxyellipticine
not being detected (Fig. 5A). The lowest level of overall ellipticine
metabolite formation was with the hepatic microsomal fractions from
HBRN mice (Fig. 5A). All metabolites were detected at signiﬁcantly
lower amounts compared to WT hepatic microsomes and 9-hydro-
xyellipticine was lower compared to HRN hepatic microsomes
(Fig. 5A).
When NADH was used as cofactor the overall formation of meta-
bolites in hepatic microsomal fractions from HRN mice was not sig-
niﬁcantly diﬀerent to fractions from WT with 9-hydroxyellipticine
being signiﬁcantly higher but 12-hydroxyellipticine being signiﬁcantly
lower and no signiﬁcant diﬀerence in the levels of 13-hydro-
xyellipticine. The overall metabolite formation in hepatic fractions from
HBRN mice was signiﬁcantly lower than with both WT and HRN frac-
tions (Fig. 5B) with 9-hydroxyellipticine being signiﬁcantly lower
compared with both WT and HRN fractions and 12-hydroxyellipticine
being signiﬁcantly lower compared with WT (Fig. 5B). The rate of el-
lipticine metabolism in the hepatic microsomal fractions correlated
with the levels of Cyp1a/3a enzymatic activity and the particular en-
zymatic cofactor used (compare Figs. 3 and 5).
Fig. 3. Enzyme activity in the pooled hepatic microsomal fractions of ellipti-
cine-treated WT, HRN and HBRN mice (n=4/group) using either NADPH or
NADH as the enzymatic cofactor. (A) POR activity was observed as nmol of
cytochrome c/mg/min and was only detected in microsomal fractions from WT
mice. (B) Cyp1a1 activity was determined by the oxidation of Sudan I to hy-
droxylated metabolites with activity being observed as nmol of total C-hydro-
xylated metabolites/mg protein/min. (C) Cyp1a2 activity was determined using
the MROD assay with activity being observed as pmol of resoruﬁn/mg protein/
min. (D) Cyp1a activity was determined using the EROD assay with activity
being observed as pmol of resoruﬁn/mg protein/min. (E) Cyp3a activity was
determined by the oxidation of testosterone to hydroxylated metabolites with
activity being observed as nmol of total C-hydroxylated metabolites/mg pro-
tein/min. Values are given as mean ± SD (n=3) from separate experiments.
Statistical analysis was performed by one-way Anova with Tukey's multiple
comparison test (*= compared to WT; #= compared to HRN. * (#)P≤ .05 **
(##)P≤ .01 *** (###)P≤ .001 **** (####)P≤ .0001).
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Fig. 4. Representative HPLC chromatograms from in vitro incubations with pooled hepatic microsomal fractions from ellipticine-pretreated WT mice with ellipticine
(ELLI) and either NADPH or NADH as cofactor. M1: 9-hydroxyellipticine; M2: 12-hydroxyellipticine; M3: 13-hydroxyellipticine. Phenacetin (PA) was used as internal
standard.
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3.4. Ellipticine-DNA adduct formation in vitro
We investigated the ability of hepatic microsomes isolated from WT,
HRN and HBRN mice to catalyse ellipticine-DNA adduct formation in
vitro (Fig. 6A). The ellipticine-DNA adduct pattern obtained by 32P-
postlabelling analysis from microsomal incubations consisted of one
major and one minor adduct spot (Fig. 6A insert) (assigned adduct 1
and 2) previously detected in vitro and in vivo (Stiborova et al., 2008;
Stiborova et al., 2012; Stiborova et al., 2012). Because the adduct spots
were incompletely separated total ellipticine-DNA adduct levels were
determined. When NADPH was used the highest ellipticine-DNA adduct
formation was seen in microsomal fractions from WT mice. There was
signiﬁcantly less DNA adduct formation with the microsomal fractions
from HRN and HBRN mice (Fig. 6A). The degree of total ellipticine-
DNA adduct formation in the hepatic microsomal fractions correlated
with the amounts of ellipticine metabolites formed (compare Fig. 5A).
When NADH was used there was no signiﬁcant diﬀerence in adduct
formation between any of the fractions (Fig. 6A).
3.5. Ellipticine-DNA adduct formation in vivo
The ellipticine-DNA adduct pattern obtained from in vivo treatments
consisted of one major adduct spot (assigned adduct 1 in Fig. 6B)
previously detected in vitro and in vivo (Stiborova et al., 2008; Stiborova
et al., 2012; Stiborova et al., 2012). Another adduct, tentative assigned
adduct spot 4, which was previously detected in ellipticine-treated rats
and mice (Stiborova et al., 2003; Stiborova et al., 2007; Stiborova et al.,
2008; Stiborova et al., 2014), was also generated in WT and HRN mice
in selected tissues (Fig. 6B insert). As this adduct was only detectable in
a few tissues (liver, lung and small intestine) in WT and HRN mice but
not HBRN its level was not quantiﬁed when adduct formation was
compared between tissues. Of the organs tested (liver, lung, kidney,
small intestine, spleen, colon and bladder) only the liver, lung and small
intestine exhibited any signiﬁcant diﬀerences between the mouse
models (Fig. 6B). DNA adduct formation in the livers of HRN and HBRN
mice was signiﬁcantly lower, by 62% and 73%, respectively, than in
WT mice. In the lung and small intestine, the levels of ellipticine-DNA
adducts were signiﬁcantly higher in HRN mice compared to WT mice.
4. Discussion
Although the role of the electron donor protein Cyb5 in the meta-
bolic activation of ellipticine has been well characterised in vitro, its
role in vivo is less understood. In the present study we have used both
HRN mice, which lack expression of hepatic POR, and HBRN mice,
which lack expression of hepatic POR and Cyb5, to investigate the
contribution of Cyb5 to the metabolic activation of ellipticine in vivo.
These mouse models have been used recently to investigate the con-
tribution of Cyb5 in the bioactivation of BaP in vivo (Reed et al., 2018).
Whilst studies with hepatic microsomal fractions demonstrated the
importance of Cyb5 in the metabolic activation of BaP in vitro, DNA
adduct formation in vivo showed that the absence of the electron donor
POR led to greatly increased levels of DNA adducts. However, the levels
of BaP-DNA adducts in HBRN mice that lacked both hepatic POR and
Cyb5 were signiﬁcantly lower than in HRN mice demonstrating a role
of Cyb5 in the metabolic activation of BaP in HRN mice. The same
approach has been utilised in this study to determine the contribution
of Cyb5 to the underlying mechanism of the P450-mediated metabolic
activation of ellipticine.
The in vitro experiments in this study were carried out using pooled
Fig. 5. Total formation of ellipticine metabolites and formation of individual metabolites during in vitro incubations with pooled hepatic microsomal fractions from
WT, HRN and HBRN mice (n=4/group) using either NADPH (A) or NADH (B) as an enzymatic cofactor. Values are given as mean ± SD (n=3) from separate
experiments. Statistical analysis was performed by one-way Anova with Tukey's multiple comparison test (*= compared to WT; #= compared to HRN. * (#)P≤ .05
** (##)P≤ .01 *** (###)P≤ .001 **** (####)P≤ .0001). ND, Not detected.
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Fig. 6. Total formation of ellipticine-DNA adducts during in vitro incubations with pooled hepatic microsomal fractions fromWT, HRN and HBRN mice (n=4/group)
using either NADPH or NADH as an enzymatic cofactor (A). Values are given as mean ± SD (n=3) from separate experiments. Statistical analysis was performed by
one-way Anova with Tukey's multiple comparison test (*= compared to WT; ** P≤ .01). Quantitative TLC 32P-postlabelling analysis of ellipticine-DNA adducts in
organs of WT, HRN and HBRN mice treated i.p with 10mg/kg bw ellipticine for 24 h (B). Values are given as mean ± SD (n=4); DNA isolated from tissues of
individual mice was analysed for each group. Statistical analysis was performed by one-way Anova with Tukey's multiple comparison test (*= compared to WT; *
P≤ .05). Inserts: (A) Autoradiographs of ellipticine-DNA adducts in DNA isolated from these in vitro incubations. (B) Autoradiographs of ellipticine-DNA adducts in
liver, lung, kidney, colon, small intestine, bladder and spleen tissues in WT, HRN and HBRN mice. The origin on the TLC plate, at the bottom left-hand corners, was
cut oﬀ before exposure. Adduct spots 1 and 2 are formed in deoxyguanosine residues of DNA by the ellipticine metabolites 13-hydroxy- and 12-hydroxyellipticine,
respectively.
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hepatic microsomal fractions. When NADPH was used as cofactor to
examine the POR-dependent pathway, P450 enzyme activity assays
clearly showed a reduction in Cyp1a activity as electron donors were
lost. However, whilst signiﬁcant reductions in total ellipticine meta-
bolite and ellipticine-DNA adduct formation were found compared to
WT there was no signiﬁcant diﬀerence between HRN and HBRN frac-
tions themselves, correlating with the results from Cyp3a marker ac-
tivity. When the NADH-dependent Cyb5R pathway was investigated,
there was higher Cyp1a enzyme activity in the microsomal fractions of
HRN mice than in those of WT mice. In the microsomal fractions from
HBRN mice the activity was signiﬁcantly lower relative to WT mice,
indicating that increased NADH-dependent activity is caused by the
increased expression of Cyb5. Cyp1a activity did not correlate with
total ellipticine metabolite formation as there was no signiﬁcant dif-
ference between the WT and HRN fractions with only HBRN fractions
showing signiﬁcant reductions compared to both WT and HRN.
Although this reduction in total metabolite formation would be sug-
gestive of the contribution of Cyb5 to the activation of ellipticine,
whilst all metabolites formed by HBRN fractions were reduced com-
pared to WT, the only metabolite signiﬁcantly reduced in HBRN frac-
tions compared to HRN fractions was 9-hydroxyellipticine, a detoxica-
tion metabolite. This supports previous results in the HRN mouse with
9-hydroxyellipticine being aﬀected by the absence of POR and P450
activity more than other metabolites (Stiborova et al., 2008). Total el-
lipticine-DNA adduct formation in vitro in the presence of NADH was
lower than when NADPH was present, but not signiﬁcantly diﬀerent
between the mouse lines.
Previous studies with reconstituted CYP1A1 and CYP1A2 showed
that the presence of Cyb5 in the reaction mixture alters the resulting
ellipticine metabolites proﬁles, with a shift from detoxication metabo-
lites, 9-hydroxy- and/or 7-hydroxyellipticine, to metabolites that can
ultimately form DNA adducts, 12-hydroxy- and/or 13-hydro-
xyellipticine (Kotrbova et al., 2011). These ﬁndings were echoed in
studies using human CYP3A4 in Supersomes™, which found that the
presence of Cyb5 in the reaction mixture also led to an increase in
formation of 12-hydroxy and 13-hydroxyellipticine (Stiborova et al.,
2012; Stiborova et al., 2012; Stiborova et al., 2017). In the present
study we found that hepatic microsomal fractions from HBRN mice that
do not possess either electron donor, metabolite formation was sig-
niﬁcantly lower than with WT fractions regardless of the cofactor used.
In the hepatic microsomal fractions from HRN mice in the presence of
NADH, however, the formation of 9-hydroxyellipticine was sig-
niﬁcantly higher than with microsomal fractions from WT mice whilst
metabolites associated with metabolic activation were signiﬁcantly
lower (i.e. 12-hydroxyellipticine). The absence of Cyb5 in hepatic mi-
crosomal fractions from HBRN mice correlates with the ﬁndings from
reconstituted P450 enzymes suggesting Cyb5 contributes to the acti-
vation of ellipticine in vitro (Kotrbova et al., 2011; Stiborova et al.,
2012; Stiborova et al., 2012; Stiborova et al., 2017). This correlation,
however, does appear to be limited to ellipticine metabolite formation.
Previous studies (Poljakova et al., 2005; Kotrbova et al., 2011;
Stiborova et al., 2013; Stiborova et al., 2017) found that the shift in
metabolite production was coupled with an increase in in vitro ellipti-
cine-DNA adduct formation. The hepatic microsomal fractions from the
present study, however, found no signiﬁcant diﬀerence between DNA
adduct formation in HRN or HBRN hepatic microsomal fractions re-
gardless of the enzymatic cofactor used.
The present in vivo results correlated with in vitro ellipticine-DNA
adduct formation when NADPH was used as cofactor. Both HRN and
HBRN mice showed signiﬁcantly lower (~60–70%) hepatic ellipticine-
DNA adduct formation than WT mice, but there was no signiﬁcant
diﬀerence between the two knockout lines. The HRN results correlate
with a previous study that found a 65% reduction in hepatic DNA ad-
duct formation in HRN mice (Stiborova et al., 2008) suggesting a
greater contribution of the POR-dependent pathway to the bioactiva-
tion of ellipticine in vivo. In vitro experiments carried out in the present
study with the cofactor NADH showing Cyb5R-dependent pathways
contributing to ellipticine bioactivation in HRN mice correlated with in
vivo adduct formation in the lungs and small intestine of HRN mice,
suggesting that the Cyb5/Cyb5R systems contributes to ellipticine-DNA
adduct formation in these extrahepatic organs of HRN mice. Ellipticine-
DNA adduct formation in the extrahepatic organs of WT and HRN mice
has been observed previously with HRN mice showing higher levels
than WT mice, suggesting that ellipticine or its metabolites are being
distributed via the bloodstream to organs and tissues with the metabolic
capacity to oxidatively activate ellipticine (Stiborova et al., 2008). In
the present study there was a trend for ellipticine-DNA adduct levels to
be higher in the extrahepatic organs, i.e. kidney, colon and bladder, of
both HRN and HBRN mice compared to WT mice, with levels of ellip-
ticine-DNA adduct formation being signiﬁcantly higher in the lungs and
small intestines of HRN mice compared to WT mice. This could be due
to the decreased levels of P450-mediated ellipticine metabolism in the
livers of HRN and HBRN mice causing higher amounts of ellipticine to
be distributed to extrahepatic organs. Levels of ellipticine-DNA adduct
formation were not signiﬁcantly diﬀerent in any of the extrahepatic
organs of HBRN mice compared to WT mice, suggesting that increased
levels of activated ellipticine in the extrahepatic organs could be at-
tributed to Cyb5 activity in the HRN mice.
The signiﬁcant reduction in DNA adduct formation in the livers of
HRN and HBRN mice indicates that P450 enzymes are responsible for
the majority of ellipticine activation, although hepatic DNA adduct
formation in HRN and HBRN mice is still detectable. It is possible that
ellipticine activation still occurs due to the greater induction of hepatic
P450 enzymes in HRN and HBRN mice compared to WT mice combined
with expression of POR and Cyb5 in the non-parenchymal liver cells.
Further investigation of this would require isolation and culture of
hepatocytes and non-parenchymal liver cells from HBRN mice and ex-
posure of these cells to ellipticine for subsequent ellipticine-DNA adduct
analysis which was beyond the scope of the present study. The bioac-
tivation of ellipticine can also be catalysed via P450-independent me-
chanisms that are not dependent on POR or Cyb5. Numerous perox-
idases such as bovine LPO, human MPO, ovine COX-2 and plant HRP
have previously been shown to activate ellipticine to reactive metabo-
lites, which form two DNA adducts analogous to those generated by the
P450-mediated reactions (Stiborova et al., 2007). Of the ellipticine
metabolites, peroxidases predominantly form an ellipticine dimer
(Stiborova et al., 2007), and generate the reactive intermediate ellip-
ticine-13-ylium that is responsible for formation of adduct 1 (Fig. 1).
Another metabolite detected was the N2-oxide (Fig. 1), interestingly one
that is also generated by the oxidation of ellipticine by P450s and forms
adduct 2 in vitro after the N2-oxide undergoes the Polonowski re-ar-
rangement to form 12-hydroxyellipticine (Poljakova et al., 2005). In
several tissues in ellipticine-treated WT and HRN mice (present study)
we detected adduct 4 which previously has also been observed in el-
lipticine-treated rats (Stiborova et al., 2003; Stiborova et al., 2007;
Stiborova et al., 2014) and in vitro studying ellipticine-DNA adduct
formation recombinant human CYP3A4 expressed in Supersomes™
(Stiborova et al., 2011). However, the structure of this adduct has not
yet been elucidated. Peroxidase-mediated ellipticine activation was also
shown to generate two additional DNA adducts (Stiborova et al., 2007)
that were, however, not detected in this study.
Studies with hepatic microsomal fractions from WT and HRN mice
from mice pretreated with BaP were carried out to investigate the eﬀect
of enzyme induction on activation of ellipticine in vitro (Stiborova et al.,
2013). Microsomal incubations with ellipticine, DNA and arachidonic
acid, a cofactor for COX-dependent oxidation, showed DNA adduct
formation at a level similar to that when POR, Cyp1a or Cyp3a enzymes
were inhibited in hepatic microsomal fractions from untreated mice. In
the hepatic microsomal fractions from mice pretreated with BaP, el-
lipticine-DNA adduct formation with arachidonic acid was higher, very
likely due to induction of COX by BaP, with no signiﬁcant diﬀerence
between fractions from WT and HRN mice (Stiborova et al., 2013). This
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participation of COX in hepatic microsomal fractions from HRN mice
suggests that peroxidases could be responsible for the activation of el-
lipticine in the livers of HRN and HBRN mice.
In summary, this study has shown that whilst POR contributes to the
bioactivation of ellipticine in vitro, the role of Cyb5 is still rather un-
clear. The in vivo role of Cyb5 in the activation of ellipticine in both
HRN and HBRN mice appears to be less important. These ﬁndings
conﬁrm the importance of P450 enzymes in the bioactivation of ellip-
ticine. Whilst non-parenchymal liver cells may play a role in catalysing
P450-mediated bioactivation of ellipticine in HRN and HBRN mice, the
presence of ellipticine-DNA adducts in the livers of HRN and HBRN
mice suggests the involvement of a P450-independent bioactivation
mechanism.
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